Eva Feldman

FDA Approves Phase II Of U-M Stem Cell Trial For ALS For nearly two years, University of Michigan neurologist Eva Feldman, M.D., has led the nation's first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig's disease.
ALS Patients Approved For More Stem CellsThree patients with amyotrophic lateral sclerosis will be permitted to receive a second dose of stem cells delivered directly to the spinal cord, in a clinical trial being led by the University of Michigan's Eva Feldman, M.D.
Awards and Certifications From September 21The latest awards and industry certifications from Michigan's technology-focused companies and institutions
Stem Cell Summit: Cure For Paralysis And More?
Best Winter Festivals In Metro Detroit
Thanksgiving Parade Guide

Watch & Listen